Bristol Myers' legacy drug sales plunged 20% amid generic erosion and Medicare changes, spotlighting its shift to a newer ...

Bristol-Myers Squibb faces patent losses and growth headwinds despite pipeline gains, debt cuts, and dividends. Read why BMY ...

Breaking down what patients should know about each FDA therapeutic approval from June 2025 across various oncology ...

Bristol Myers and Celgene are being sued in an antitrust suit, alleging they used fraud, sham litigation, and reverse ...

Dr. Joshua Sabari and Dr. Nausheen Ahmed sat down to discuss topline takeaways in the realm of hematologic malignancies ...

Incyte INCY has put up a good performance in the past three months. Shares of the company have gained 9.2% against the industry’s decline of 1.3%. The stock has also outperformed the sector in the ...

CAR T-cell therapy targeting B-cell maturation antigen (BCMA) has become a game changer for patients with relapsed or ...

FDA approves tafasitamab with lenalidomide and rituximab, offering a groundbreaking chemotherapy-free treatment for relapsed ...

Shares of Dr Reddy's Laboratories decreased by 2 per cent to Rs 1,317 in morning trading, following Citi Research's decision ...

This Big Pharma company is positioned for a rebound while continuing to pay investors a sizable dividend yield.

Citi believes that market expectations for the GLP-1 opportunity in Canada may be too optimistic, based on its latest deep ...

Dr. Reddy launched generic Revlimid (multiple myeloma) in September 2022 or H2FY23. The US segment (45 per cent of FY25 sales) reported sales growth in FY22-25 of 24 per cent CAGR compared with 8 ...